Younes, A. Et Al. 2019. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. LANCET HAEMATOLOGY , vol.6, no.2 .

Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, B., ... Nagler, A.(2019). Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. LANCET HAEMATOLOGY , vol.6, no.2.

Younes, Anas Et Al. "Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study," LANCET HAEMATOLOGY , vol.6, no.2, 2019

Younes, Anas Et Al. "Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study." LANCET HAEMATOLOGY , vol.6, no.2, 2019

Younes, A. Et Al. (2019) . "Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study." LANCET HAEMATOLOGY , vol.6, no.2.

@article{article, author={Anas Younes Et Al. }, title={Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study}, journal={LANCET HAEMATOLOGY}, year=2019}